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Reverse epidemiology of blood
pressure in dialysis patients
To the Editor: Agarwal implies that the paradoxical
associations found between higher blood pressure (BP)
values and better survival are limited to prevalent dialy-
sis patients [1]. We recently studied a 15-month cohort of
40,933 hemodialysis patients and found that high predial-
ysis systolic BP conferred survival advantages even after
adjustment for dialysis vintage categories, among others
[2]. Shoji et al showed that intradialysis hypotension and
orthostatic hypotension after hemodialysis are significant
and independent factors affecting mortality in hemodial-
ysis patients [3]. A recent study by Lopez-Gomez et al
showed that a high predialysis BP was frequently ob-
served in those hemodialysis patients who had the highest
interdialytic weight gain, increased food intake, better nu-
tritional status, and improved clinical outcome, including
better survival [4]. Hence, we caution against categoric
dismissal of the reverse epidemiology of BP, only because
they appear counterintuitive based on observations from
the general population. Indeed, the reverse epidemiol-
ogy is not restricted to BP, but has also been observed
with regard to obesity, hypercholesterolemia, and hyper-
homocysteinemia, among others [5].
Moreover, the reverse epidemiology is not restricted
to dialysis patients but may also exist in over 20 mil-
lion Americans, including patients with heart failure,
advanced age, malignancies, AIDS, and several other
chronic disease states [5]. Therefore, we believe that
the reverse epidemiology phenomenon deserves a more
global and inclusive point of view. Further studies are
needed to explore mechanisms behind such paradoxic as-
sociations, and to assess what BP range is the best for dial-
ysis patients. Examining methods to improve nutritional
status and inflammation in dialysis and other similar pa-
tient populations may be a crucial step to that direction.
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Reply from the Authors
Many of the answers that explain the paradoxic associa-
tion between low blood pressure (BP) and high mortality
lie within the studies that Kalantar-Zadeh et al cite. First,
the large study they have performed has only a two-year
follow-up, which may be insufficient to reveal hyperten-
sion as a risk factor for cardiovascular disease [1]. Cor-
rection for the dialysis vintage does not remove the bias
that exists in a prevalent cohort study; antihypertensive
drug use or cardiovascular disease, especially heart fail-
ure, have not been considered when studying the impact
of BP on total mortality. For example, patients with heart
failure may have a greater mortality despite a lower BP
compared to patients without heart failure on hemodial-
ysis [2]. A relationship between good nutrition and hy-
pertension suggests that favorable clinical characteristics
are associated with a higher BP, but does not suggest that
lowering BP or limiting sodium intake in those with hy-
pertension is associated with worse outcomes [3]. Shoji
et al relate intradialytic—not interdialytic—hypotension
as a risk factor for mortality [4]. Epidemiology helps us
understand the nature and scope of the problem. Causal-
ity cannot be deduced from paradoxically relating low
BP to increased mortality. The correlation of lower BP
with short-term mortality may simply be a reflection of a
higher level of sickness. Controlling hypertension is pro-
tective in long-term cohort studies [5], and in studies that
examine the influence of systolic hypertension on car-
diovascular events rather than total mortality [6]. Hence,
lowering BP through nonpharmacologic and pharmaco-
logic means should be a key element of management of
